mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer (Q60395350)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

title

mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Shun-Qing Liang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Duo Xu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Laurène Froment

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Haitang Yang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Erik Vassella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Zhang Yang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Ren-Wang Peng

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Elias D Bührer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Sean R R Hall

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Gregor J Kocher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Ralph A Schmid

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

language of work or name

English

0 references

publication date

31 August 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

page(s)

622-636

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

Comprehensive molecular profiling of lung adenocarcinoma

20 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Drugging the undruggable RAS: Mission possible?

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Cancer drug resistance: an evolving paradigm

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Molecular mechanisms of mTOR-mediated translational control

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Rapamycin: one drug, many effects

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

3D cell culture systems modeling tumor growth determinants in cancer target discovery

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

A combinatorial strategy for treating KRAS-mutant lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non-Small Cell Lung Cancers.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Spheroid-based drug screen: considerations and practical approach

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays

1 reference

https://api.crossref.org/works/10.1038%2FS41388-018-0479-6

7 January 2021

10.1038/S41388-018-0479-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30171261%20AND%20SRC:MED&resulttype=core&format=json